# 2025年12月25日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 磷脂翻转酶1（PLSCR1）在甲型流感病毒（IAV）感染中调控干扰素-λ受体1（IFN-λR1）及IFN-λ信号通路。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41439508)
**期刊：** eLife
**PMID：** 41439508
**DOI：** 10.7554/eLife.104359

### 第一部分 原文与翻译

**英文原标题：** Phospholipid scramblase 1 (PLSCR1) regulates interferon-lambda receptor 1 (IFN-λR1) and IFN-λ signaling in influenza A virus (IAV) infection.

> **英文摘要：**
> Phospholipid scramblase 1 (PLSCR1) is an interferon-stimulated gene (ISG) that has several known anti-influenza functions. However, the mechanisms in relation to its expression compartment and enzymatic activity have not been completely explored. Moreover, only limited animal models have been studied to delineate its role at the tissue level in influenza infections. Our results showed that influenza A virus (IAV)-infected  mice exhibited exacerbated body weight loss, decreased survival rates, heightened viral replication, and increased lung damage. Interestingly, transcriptomic analyses demonstrated that Plscr1 was required for the expression of type 3 interferon receptor (Ifn-λr1) upon IAV infection by binding to its promoter. In addition, PLSCR1 interacted with IFN-λR1 on the cell surface of pulmonary epithelial cells following IAV infection, suggesting it also modulated IFN-λ signaling via protein-protein interactions. The lipid scramblase activity of PLSCR1 was found to be dispensable for its anti-flu activity. Finally, single-cell RNA sequencing data indicated that  expression was significantly upregulated in ciliated airway epithelial cells in mice following IAV infection. Consistently, mice with ciliated epithelial cell-specific Plscr1 overexpression showed reduced susceptibility to IAV infection, less inflammation, and enhanced Ifn-λr1 expression, suggesting that Plscr1 primarily regulates type 3 IFN signaling as a cell-intrinsic defense factor against IAV in ciliated airway epithelial cells. Our research will elucidate virus-host interactions and pave the way for the development of novel anti-influenza drugs that target human elements like PLSCR1, thereby mitigating the emergence of drug-resistant IAV strains.

> **中文摘要：**
> 磷脂翻转酶1（PLSCR1）是一种由干扰素刺激的基因（ISG），具有多种已知的抗流感功能。然而，其表达位置及酶活性相关的机制尚未得到完全研究。此外，仅有有限的动物模型用于描绘其在流感感染中组织层面的作用。我们的结果显示，感染甲型流感病毒（IAV）的小鼠表现出更严重的体重下降、生存率降低、病毒复制加剧以及肺损伤加重。有趣的是，转录组分析表明，Plscr1通过结合其启动子，在IAV感染过程中调控Ⅲ型干扰素受体（Ifn-λr1）的表达。此外，在IAV感染后，PLSCR1与肺上皮细胞表面的IFN-λR1发生相互作用，提示其还通过蛋白-蛋白相互作用调节IFN-λ信号通路。研究发现，PLSCR1的脂质翻转酶活性对其抗流感功能并非必需。最后，单细胞RNA测序结果显示，在IAV感染的小鼠中，纤毛气道上皮细胞中Plscr1的表达显著上调。与此一致的是，在纤毛上皮细胞中特异性过表达Plscr1的小鼠对IAV感染的易感性降低，炎症减轻，且Ifn-λr1表达增强，提示Plscr1主要通过调控Ⅲ型干扰素信号，在纤毛上皮细胞中作为一种内源性细胞防御因子抵抗IAV感染。本研究阐明了病毒与宿主的相互作用，并为开发以PLSCR1等人源因子为靶点的新型抗流感药物提供了潜在途径，从而有助于缓解耐药IAV毒株的出现。

### 第二部分 AI 大师评价

该研究系统揭示了PLSCR1在IAV感染中对IFN-λ通路的调控机制，通过转录组、单细胞测序及动物模型综合分析，指出PLSCR1不仅调节Ifn-λr1表达，还与IFN-λR1蛋白直接互作。其抗流感作用独立于脂质翻转酶活性，展示了新的抗病毒途径。研究创新性在于发现PLSCR1在纤毛上皮细胞中的特异防御功能，为抗流感治疗策略提供了人源靶点；但其在人类宿主中的临床潜能和泛病毒适用性仍需进一步验证。

---

## 2. 神经刺激辅助通气过程中膈肌用力的监测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41437368)
**期刊：** Critical care (London, England)
**PMID：** 41437368
**DOI：** 10.1186/s13054-025-05810-z

### 第一部分 原文与翻译

**英文原标题：** Monitoring diaphragmatic effort during neurostimulation-assisted ventilation.

> **英文摘要：**
> RATIONALE: Diaphragm neurostimulation-assisted ventilation (DNAV) can improve cardiopulmonary function during passive mechanical ventilation. However, this technique requires a reliable method to monitor and titrate diaphragmatic loading to avoid both insufficient and excessive diaphragmatic stimulation.
> 
> OBJECTIVE: To establish whether the reduction in airway pressure-time product (ΔPTPaw) obtained during diaphragm neurostimulation in assist control volume-controlled mode accurately quantifies the magnitude of respiratory muscle effort elicited by neurostimulation.
> 
> METHODS: This was a secondary analysis of the STIMULUS trial. Diaphragm neurostimulation was titrated across four levels targeting progressive occlusion pressures of 0, - 5, - 10, and - 15 cm H₂O at two PEEP levels. At each level, airway, esophageal, and gastric pressures were recorded to compute transdiaphragmatic pressure-time product (PTPdi), respiratory muscles pressure-time product (PTPmus), and ΔPTPaw, defined as the difference in airway pressure-time product between non-stimulated and stimulated breaths. Linear mixed-effects models, Bland-Altman analyses, and receiver operating characteristic (ROC) curves were used to assess agreement and discriminative ability.
> 
> MEASUREMENTS AND MAIN RESULTS: Twelve patients contributed 494 high-quality respiratory cycles (63% of recorded cycles). Valid Pdi data were available in nine patients. Increasing neurostimulation was associated with higher PTPdi and PTPmus and a corresponding reduction in PTPaw. ΔPTPaw was correlated with both PTPdi (R² = 0.82) and PTPmus (R² = 0.92), with good agreement observed (limits: - 4 to 44 cm H₂O·s/min for PTPdi, and - 5 to 39 cm H₂O·s/min for PTPmus). ΔPTPaw demonstrated excellent discrimination for inadequate (area under receiver operating characteristic curve, AUROC ≥ 0.94) and excessive (AUROC ≥ 0.86) diaphragmatic effort.
> 
> CONCLUSIONS: ΔPTPaw is a reliable, non-invasive surrogate for monitoring diaphragm loading during DNAV under assist-controlled volume-controlled mode and may guide neurostimulation titration in mechanically ventilated patients.

> **中文摘要：**
> 研究背景：膈肌神经刺激辅助通气（DNAV）可以在被动机械通气过程中改善心肺功能。然而，该技术需要一种可靠的方法来监测并调整膈肌负荷，以避免膈肌刺激不足或过度。
> 
> 研究目的：确定在辅助控制、容量控制模式下，通过膈肌神经刺激所获得的气道压力-时间积（ΔPTPaw）的降低，是否能够准确量化神经刺激引起的呼吸肌用力程度。
> 
> 研究方法：本研究为 STIMULUS 试验的二次分析。研究中在两个不同的呼气末正压（PEEP）水平下，对膈肌神经刺激进行了四个梯度的调节，分别对应目标闭合压为 0、-5、-10 和 -15 cmH₂O。在每个水平下，记录气道、食管及胃内压力，以计算跨膈压力-时间积（PTPdi）、呼吸肌压力-时间积（PTPmus）及 ΔPTPaw（定义为非刺激与刺激呼吸之间的气道压力-时间积差值）。采用线性混合效应模型、Bland-Altman 分析及受试者工作特征（ROC）曲线评估一致性及区分能力。
> 
> 测量结果与主要发现：共有 12 名患者贡献了 494 个高质量呼吸循环（占记录循环的 63%），其中 9 名患者获得了有效的 Pdi 数据。随着神经刺激增强，PTPdi 和 PTPmus 均增加，而 PTPaw 相应减少。ΔPTPaw 与 PTPdi（R² = 0.82）及 PTPmus（R² = 0.92）均呈显著相关，且表现出良好一致性（PTPdi 的一致性界限：-4 至 44 cmH₂O·s/min，PTPmus 的一致性界限：-5 至 39 cmH₂O·s/min）。ΔPTPaw 在识别膈肌用力不足（ROC 曲线下面积 AUROC ≥ 0.94）及过度（AUROC ≥ 0.86）方面均表现出极佳的区分能力。
> 
> 结论：ΔPTPaw 是一种可靠的、非侵入性的指标，可用于在辅助控制-容量控制模式下监测 DNAV 过程中膈肌负荷，并可为机械通气患者的神经刺激强度调整提供指导。

### 第二部分 AI 大师评价

本研究旨在验证气道压力-时间积变化（ΔPTPaw）能否作为膈肌神经刺激辅助通气中监测膈肌用力的非侵入性指标。通过对 STIMULUS 试验的二次分析，研究者在不同刺激强度与 PEEP 条件下评估了 ΔPTPaw 与 PTPdi、PTPmus 的相关性。结果显示 ΔPTPaw 与膈肌及呼吸肌用力呈强相关且具良好一致性，同时具有卓越的鉴别膈肌用力不足或过度的能力。该研究的创新点在于提出并验证了一种无需侵入监测即可量化膈肌负荷的新方法，但样本量仍有限，尚需进一步临床验证。

---

## 3. 一类短链抗菌肽家族通过多模式作用机制显示出抗感染活性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41433402)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41433402
**DOI：** 10.1128/aac.01343-25

### 第一部分 原文与翻译

**英文原标题：** A short antimicrobial peptides family demonstrates efficacy to infection via a multimodal mechanism of action.

> **英文摘要：**
> The escalating threat posed by multidrug-resistant (MDR) Gram-negative "superbugs" has intensified. Short antimicrobial peptides (SAMPs) have emerged as promising therapeutics with sustained potency and cost-effectiveness against drug-resistant infections. Here, we report a family of 15-residue SAMPs derived through modifying related amino acids of Kassporin-KS1 (FA), utilizing database-filtering technology to identify the most probable structural parameters related to Gram-negative bacteria. Most SAMPs exhibit sub-μM antimicrobial activity with reliable stability and low toxicity. Notably, KR and RK demonstrate significant efficacy in combating biofilms and sepsis infections . Furthermore, the acquisition of resistance by strains to SAMPs was not observed, primarily due to the multimodal antimicrobial mechanisms of SAMPs. We revealed that the multimodal mechanisms of SAMPs encompass unregulated membrane destabilization, induction of apoptotic-like death pathway, and interference with normal physiological processes. Overall, the rational design strategies proposed herein can be implemented to develop potent antimicrobial agents targeting MDR bacteria.

> **中文摘要：**
> 多重耐药（MDR）革兰氏阴性“超级细菌”带来的威胁正在不断加剧。短链抗菌肽（SAMPs）作为一种具有持续效力和高性价比的抗耐药感染候选治疗手段正逐渐崭露头角。在本研究中，我们报告了一类由 Kassporin-KS1（FA）相关氨基酸修饰而得的 15 个残基的短链抗菌肽家族，利用数据库筛选技术识别与革兰氏阴性菌相关的最可能结构参数。多数 SAMPs 表现出亚微摩尔级别的抗菌活性，并且具有可靠的稳定性和较低的毒性。值得注意的是，KR 和 RK 在对抗生物膜及脓毒症感染方面展现出显著的疗效。此外，未观察到菌株对 SAMPs 产生耐药性，这主要归因于 SAMPs 的多模式抗菌作用机制。我们揭示，SAMPs 的多模式机制包括非受控的膜去稳定化、诱导类凋亡性死亡通路以及干扰正常生理过程。总体而言，本文提出的理性设计策略可用于开发针对多重耐药细菌的高效抗菌剂。

### 第二部分 AI 大师评价

本研究针对多重耐药革兰氏阴性菌提出了一类经过理性设计的短链抗菌肽家族，其通过数据库筛选优化得到结构参数。实验显示这些肽具备强效、稳定且低毒的抗菌活性，部分成员在生物膜与脓毒症模型中表现优越。作者阐明其多模式抗菌机制，使其不易诱发耐药性。该研究在抗耐药菌药物开发方面具有创新意义，但仍需通过体内安全性与药代动力学研究进一步验证。

---

## 4. 从全球健康视角探讨美国肾脏病学会关于需透析急性肾损伤门诊管理的指南

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41433093)
**期刊：** Clinical journal of the American Society of Nephrology : CJASN
**PMID：** 41433093
**DOI：** 10.2215/CJN.0000000988

### 第一部分 原文与翻译

**英文原标题：** A Global Health Perspective on the ASN Guidance for Outpatient Management of Dialysis-Requiring AKI.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文从全球健康的角度审视美国肾脏病学会（ASN）针对需透析急性肾损伤患者门诊管理的最新指南。文章的目的在于统一国际视野下的临床实践标准，促进资源受限地区与高收入国家的管理经验互通。虽然摘要缺失，但可推测其关注的重点包括透析启动标准、随访流程以及门诊化管理的可行性。其创新在于从全球健康公平视角解析现行指南，但内容可能缺乏具体实施策略与多地区数据验证。

---

## 5. 由M1UK谱系引起的侵袭性A族链球菌感染患者的死亡率：英格兰和威尔士的一项回顾性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41099520)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41099520
**DOI：** 10.1093/cid/ciaf492

### 第一部分 原文与翻译

**英文原标题：** Mortality Among Patients With Invasive Group A Streptococcal Infections Caused by the M1UK Lineage: A Retrospective Cohort Study in England and Wales.

> **英文摘要：**
> BACKGROUND: The M1UK sublineage of Streptococcus pyogenes has driven recent post-pandemic surges in invasive group A streptococcal (iGAS) disease. We assessed case fatality rate (CFR) among patients with emm1 iGAS in England and Wales, and then compared outcomes associated with M1UK and ancestral emm1 lineages.
> 
> METHODS: We linked emm1 iGAS cases (December 2009-July 2022) with demographic and mortality records. Lineage was determined for isolates collected in 2010, 2013-2016, and 2020 via whole-genome sequencing or allele-specific PCR. Seven- and 30-day all-cause CFRs were estimated. Univariate and multivariate models assessed the association between lineage and risk of death.
> 
> RESULTS: Among 4952 emm1 iGAS cases, lineage was assigned to 1356. The 30-day CFR was 24.4% for M1UK, 22.3% for M1global, 10.5% for M123SNP, and 10.3% for M113SNP. After adjustment for age and sex, lineage was not a significant predictor of 7- or 30-day mortality. Survival analysis showed rapid progression to death in both M1UK and M1global cases: 63.7% of deaths occurred within 1 day of diagnostic sampling. Among children under 15 years, 56.3% of fatal cases died before sampling, and 95.6% within 1 day of sampling.
> 
> CONCLUSIONS: Mortality did not differ significantly between M1UK and M1global lineages, but more studies are required. Overall mortality from emm1 S. pyogenes remains strikingly high. The rapid time to death underscores the need for preventive measures and rapid diagnostic tools that act prior to culture-based confirmation, and highlights challenges for clinical trial design in iGAS.

> **中文摘要：**
> 背景：化脓性链球菌（Streptococcus pyogenes）的M1UK亚谱系驱动了近期新冠疫情后侵袭性A族链球菌（iGAS）疾病的激增。我们评估了英格兰和威尔士emm1型iGAS患者的病例致死率（CFR），并比较了与M1UK谱系及其祖源emm1谱系相关的结局。
> 
> 方法：我们将2009年12月至2022年7月间的emm1型iGAS病例与人口学及死亡记录进行关联。通过全基因组测序或等位基因特异性PCR鉴定2010年、2013–2016年及2020年收集到的菌株谱系。估算了7天和30天全因CFR。采用单变量和多变量模型评估谱系与死亡风险之间的关联。
> 
> 结果：在4952例emm1型iGAS病例中，1356例确定了谱系。30天CFR为M1UK 24.4%、M1global 22.3%、M123SNP 10.5%、M113SNP 10.3%。在调整年龄和性别后，谱系不是7天或30天死亡率的显著预测因素。生存分析显示，M1UK和M1global病例均快速进展至死亡：63.7%的死亡发生在诊断取样后1天内。15岁以下儿童中，56.3%的致死病例在采样前死亡，95.6%于采样后1天内死亡。
> 
> 结论：M1UK与M1global谱系间的死亡率无显著差异，但仍需进一步研究。总体而言，emm1型化脓性链球菌的死亡率依然令人震惊地高。极快的致死进程凸显了在培养确证前实施预防措施和快速诊断工具的必要性，并指出了iGAS临床试验设计中存在的挑战。

### 第二部分 AI 大师评价

本研究针对英格兰和威尔士的emm1型侵袭性A族链球菌感染病例进行了长期回顾性分析，评估了由M1UK和M1global谱系引起的死亡率差异。结果显示，尽管M1UK谱系与疫情后病例增加相关，但在调整混杂因素后，其7天和30天死亡率并无显著差异。研究揭示了感染后极短时间内高比例的死亡，尤其是在儿童中，强调了该感染的急性进展性。其创新性在于基于大规模国家级数据整合分析谱系特征与预后，但局限在于谱系鉴定覆盖率较低及回顾性设计所固有的偏倚。

---

## 6. 肺炎支原体感染的心脏表现：2007–2024年队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40887973)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 40887973
**DOI：** 10.1093/cid/ciaf453

### 第一部分 原文与翻译

**英文原标题：** Cardiac Manifestations of Mycoplasma pneumoniae Infections: A Cohort Study 2007-2024.

> **英文摘要：**
> BACKGROUND: While Mycoplasma pneumoniae (MP) infections typically present as a respiratory disease, extrapulmonary manifestations are well-documented. Historically, cardiac involvement has been considered uncommon (1%-2%); however, recent observations suggest higher rates, especially in MP ICU patients. This study aims to characterize the prevalence, clinical spectrum, and outcomes of hospitalized patients with MP and cardiac manifestations.
> 
> METHODS: We conducted a cohort study at Hadassah Medical Center, Jerusalem, Israel, including all inpatients with a positive PCR for MP from 2007 to mid-2024. Cardiac involvement included congestive heart failure (CHF), arrhythmias, acute coronary syndrome (ACS), peri/myocarditis, and isolated troponin elevation.
> 
> RESULTS: Of 1305 MP-positive patients (mean age 33.4 years), 152 (11.6%) were found to have cardiac involvement-17% among adult patients and 4.9% among children (P < .001). In adults, CHF and arrhythmias were most common (each 34.7%), followed by ACS (10.5%), peri/myocarditis (15.3%), and isolated troponinemia (9.7%). ICU admission occurred in 50% of adults with cardiac involvement and was significantly higher in arrhythmias and peri/myocarditis groups. In-hospital mortality among adults was high at 22.6%. Predictors of mortality included ICU admission (aOR 7.76; CI: 2.78-21.66), older age (aOR per year increase: 1.03; CI: 1.01-1.06), and primary diagnosis other than MP (aOR 3.57; CI: 1.34-9.51). Pediatric cardiac involvement primarily presented as arrhythmia (42.9%).
> 
> CONCLUSIONS: Cardiac involvement in hospitalized MP-infected adults is more common than previously recognized (17%) and carries substantial morbidity and mortality risks. Early evaluation for cardiac complications is crucial in MP-infected hospitalized patients presenting with severe illness or unexplained cardiac symptoms.

> **中文摘要：**
> 背景：尽管肺炎支原体（Mycoplasma pneumoniae，MP）感染通常表现为呼吸系统疾病，但其肺外表现已有充分证据支持。从历史上看，心脏受累被认为较为罕见（1%–2%）；然而，近期观察提示其发生率更高，尤其是在MP重症监护病房患者中。本研究旨在描述住院MP感染患者中心脏受累的发生率、临床谱及结局。
> 
> 方法：我们在以色列耶路撒冷哈达萨医学中心开展了一项队列研究，纳入2007年至2024年中期期间所有MP PCR检测阳性的住院患者。心脏受累定义包括充血性心力衰竭（CHF）、心律失常、急性冠状动脉综合征（ACS）、心包/心肌炎及单纯肌钙蛋白升高。
> 
> 结果：在1305名MP阳性患者（平均年龄33.4岁）中，152例（11.6%）存在心脏受累——成人患者为17%，儿童为4.9%（P < .001）。在成人中，CHF和心律失常最常见（各占34.7%），其次为ACS（10.5%）、心包/心肌炎（15.3%）及单纯肌钙蛋白血症（9.7%）。50%的成人心脏受累患者需入住ICU，且在心律失常和心包/心肌炎亚组中比例显著更高。成人住院期间死亡率较高，为22.6%。死亡的预测因素包括ICU收治（调整后比值比[aOR] 7.76；置信区间[CI]：2.78–21.66）、年龄增加（每岁增加aOR 1.03；CI：1.01–1.06）以及主要诊断非MP感染（aOR 3.57；CI：1.34–9.51）。儿童心脏受累主要表现为心律失常（42.9%）。
> 
> 结论：住院的MP感染成人患者中心脏受累比过去认为的更为常见（17%），并伴有显著的发病率和死亡风险。对于因重症病情或不明原因心脏症状入院的MP感染患者，及早评估心脏并发症至关重要。

### 第二部分 AI 大师评价

该研究系统评估了肺炎支原体感染中心脏受累的流行率及其临床特征，利用2007–2024年大型住院队列，揭示心脏并发症远高于传统认识。研究结果提示成人患者尤其易受累，并与较高的ICU入住率和死亡率相关。方法学基于PCR确诊病例，统计分析充分，增强了结果可信度。其创新性在于提供了长期、多年龄段数据支持，但局限在于单中心设计及回顾性性质可能影响外推性。

---

## 7. 法国两中心真实世界研究：重度烧伤患者中每周筛查循环毛霉目 DNA 并早期治疗可改善生存率。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40742288)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 40742288
**DOI：** 10.1093/cid/ciaf423

### 第一部分 原文与翻译

**英文原标题：** Weekly Screening of Circulating Mucorales DNA and Early Treatment in Severely Burned Patients Improves Survival: Real-Life Bi-center Experience in France.

> **英文摘要：**
> BACKGOUND: Invasive fungal diseases, among which includes invasive wound mucormycosis (IWM), are associated with poor outcomes in severely burned patients (SBPs). In recent years, quantitative real-time polymerase chain reaction (PCR) in serum to detect circulating Mucorales DNA (cmDNA) has shown promise for early diagnosis, reducing treatment duration and improving survival. Similarly, recent studies suggest that cmDNA detection enabled earlier diagnosis of IWM in SBPs. This retrospective study aimed to assess the impact of cmDNA-based diagnosis compared to conventional fungal culture on all-cause mortality at 30 and 100 days in SBPs.
> 
> METHODS: We retrospectively analyzed medical records of SBPs with proven or probable IWM over 2 periods, before and after the systematic implementation of cmDNA detection across 2 centers.
> 
> RESULTS: A total of 37 IWM patients were included. No significant differences were observed in clinical characteristics, treatment regimens, or disease severity between both groups. Our findings indicate that systematic cmDNA detection allowed earlier diagnosis of IWM with a median of -8 days [-16; -4] than mycological culture. The 100-day mortality was reduced from 63.6% to 30.8% (P = .071), and significantly reduced when considering only patients with total body surface area (TBSA) ≥ 30% (P = .047), in the cmDNA group. This earlier detection was associated with early initiation of liposomal amphotericin B-based therapy combined with surgery and may have contributed to the improved outcome.
> 
> CONCLUSIONS: cmDNA screening in targeted high-risk SBPs allows for earlier initiation of specific treatment and appears to improve the prognosis of IWM.

> **中文摘要：**
> 背景：侵袭性真菌感染，包括侵袭性创面毛霉菌病（IWM），在重度烧伤患者（SBPs）中与预后不良相关。近年来，利用血清定量实时聚合酶链式反应（PCR）检测循环毛霉目 DNA（cmDNA）在早期诊断、缩短治疗时间及改善生存方面显示出前景。同样，近期研究提示，cmDNA 检测可使 SBPs 的 IWM 得到更早的诊断。本研究为一项回顾性研究，旨在评估基于 cmDNA 的诊断与传统真菌培养相比，对 SBPs 30 天及 100 天全因死亡率的影响。
> 
> 方法：我们回顾性分析了两中心在系统实施 cmDNA 检测前后不同时期内，确诊或可能为 IWM 的 SBPs 的病历资料。
> 
> 结果：共纳入 37 例 IWM 患者。两组在临床特征、治疗方案及疾病严重程度方面无显著差异。研究结果显示，系统性 cmDNA 检测较真菌学培养能够更早诊断 IWM，中位提前 8 天（[-16；-4]）。100 天死亡率从 63.6% 降至 30.8%（P = 0.071），在全身烧伤面积（TBSA）≥30% 的患者中，cmDNA 组死亡率降低具有统计学显著性（P = 0.047）。这种更早的检测使得基于脂质体两性霉素 B 的治疗与手术得以及早启动，可能促进了预后的改善。
> 
> 结论：在高危 SBPs 中实施 cmDNA 筛查，可实现特异性治疗的早期启动，并有助于改善 IWM 的预后。

### 第二部分 AI 大师评价

该研究系统评估了在重度烧伤患者中每周进行循环毛霉目 DNA 筛查的临床价值。通过两中心的回顾性数据比较，研究发现基于 cmDNA 的分子检测可显著提前 IWM 诊断时间，并在部分高危患者中显著降低 100 日死亡率。其创新在于将实时 PCR 技术应用于感染早期监测，实现感染控制的前移。尽管样本量有限且为回顾性设计，但结果为烧伤危重症中毛霉菌病的早期诊治提供了实证依据与策略指引。

---

## 8. 2023年赤道几内亚经实验室确诊的马尔堡病毒病患者病例系列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40274600)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 40274600
**DOI：** 10.1093/cid/ciaf208

### 第一部分 原文与翻译

**英文原标题：** Case Series of Patients With Laboratory-Confirmed Marburg Virus Disease in 2023 in Equatorial Guinea.

> **英文摘要：**
> BACKGROUND: Marburg virus disease (MVD) is a severe viral infection caused by the Marburg marburgvirus species. In February 2023, Equatorial Guinea declared its first outbreak. This case series describes the natural history of MVD in 5 patients with laboratory-confirmed disease.
> 
> METHODS: Patients with confirmed MVD who were admitted to the national treatment center in Bata, Equatorial Guinea were monitored for vital signs and symptoms. Comprehensive clinical data were collected to understand the progression and outcome of the disease.
> 
> RESULTS: Five patients were confirmed to have MVD. Three male healthcare workers received a diagnosis diagnosed early in their disease and subsequently survived. The other 2 patients, both female, were admitted later in their disease progression and died within 24 hours of admission. Four patients received remdesivir under a protocol for the monitored emergency use of unregistered and experimental interventions. The early symptoms were nonspecific, with rapid progression to more severe conditions in the later stages of the disease. Early treatment with remdesivir showed the drug to be well tolerated.
> 
> CONCLUSIONS: Contrary to some reports and the recommended case definition for MVD, our patients presented with a rash but did not exhibit vomiting or diarrhea. Hemorrhagic signs were solely observed in the terminal stage, preceding demise. Despite the limited sample size, these findings emphasize the importance of tailoring the case definition to the specific outbreak. Further evidence on the efficacy and safety of therapeutics for MVD, including remdesivir, should be gathered through well-designed trials during future epidemic responses.

> **中文摘要：**
> 背景：马尔堡病毒病（MVD）是一种由马尔堡病毒属马尔堡病毒种引起的严重病毒感染。2023年2月，赤道几内亚宣布其首次暴发。本病例系列报告描述了5例经实验室确诊的MVD患者的自然病程。
> 
> 方法：在赤道几内亚巴塔国家治疗中心收治的确诊MVD患者接受生命体征和症状监测。采集了全面的临床数据，以理解疾病的进展及结局。
> 
> 结果：共有5名患者被确诊为MVD。其中3名男性医护人员在疾病早期即获得诊断并最终存活。另2名女性患者在疾病晚期入院，并在入院后24小时内死亡。4名患者在受控的未注册及实验性干预紧急使用方案下接受了瑞德西韦治疗。疾病早期症状缺乏特异性，随后迅速进展为更严重的病情。早期使用瑞德西韦治疗显示药物耐受性良好。
> 
> 结论：与部分报告及当前推荐的MVD病例定义相反，本研究患者虽然出现皮疹，却并未表现出呕吐或腹泻。出血体征仅在终末阶段、死亡前出现。尽管样本量有限，这些发现强调了根据特定暴发情况调整病例定义的重要性。未来应通过精心设计的试验进一步获取包括瑞德西韦在内的MVD治疗药物的疗效与安全性证据，以支持后续的疫情应对。

### 第二部分 AI 大师评价

本研究报道了2023年赤道几内亚首次马尔堡病毒病暴发期间的5例实验室确诊病例，详细描述了其临床进展和结局。研究发现早期确诊并使用瑞德西韦的患者预后较好，而晚期入院者病情进展迅速并在短期内死亡。研究指出疾病早期症状缺乏特异性，部分病例表现与既往定义不符，提示需依据实际疫情调整病例定义。尽管样本量有限，该研究为MVD的临床特征及潜在治疗策略提供了有价值的初步证据。

---

## 9. 接受T细胞连接剂癌症免疫治疗患者的感染性并发症：来自REISAMIC注册研究的描述性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40165410)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 40165410
**DOI：** 10.1093/cid/ciaf164

### 第一部分 原文与翻译

**英文原标题：** Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry.

> **英文摘要：**
> We investigated infectious complications and the associated risk factors in 181 patients undergoing T-cell engagers for malignancies. Infections were primarily observed in patients with hematological diseases or heavily pre-treated. Mortality due to infectious complications was 2.8%. Concomitant medications with corticosteroids or tocilizumab did not significantly impact the incidence of infections.

> **中文摘要：**
> 我们在181名接受T细胞连接剂治疗恶性肿瘤的患者中调查了感染性并发症及其相关风险因素。感染主要发生在患有血液系统疾病或既往接受大量治疗的患者中。由感染性并发症导致的死亡率为2.8%。同时使用皮质类固醇或托珠单抗等药物并未显著影响感染的发生率。

### 第二部分 AI 大师评价

该研究利用REISAMIC注册数据库，对接受T细胞连接剂治疗的癌症患者感染并发症进行了系统描述。结果显示感染多见于血液系统肿瘤或多线治疗患者，整体感染相关死亡率较低。研究提示皮质类固醇或托珠单抗的合用对感染风险无显著影响。该研究为T细胞连接剂相关感染风险管理提供了真实世界证据，但其描述性设计限制了因果推断。

---

## 10. 美国成年人中糖皮质激素、合并免疫抑制及耶氏肺孢子菌肺炎预防的研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40117207)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 40117207
**DOI：** 10.1093/cid/ciaf147

### 第一部分 原文与翻译

**英文原标题：** Glucocorticoids, Concomitant Immunosuppression, and Pneumocystis jirovecii Pneumonia Prophylaxis Among US Adults.

> **英文摘要：**
> The impact of glucocorticoids, comorbid conditions, and immunosuppressive therapies on Pneumocystis jirovecii pneumonia risk remains understudied, and prophylaxis is underused. Among US adults in TriNetX prescribed glucocorticoids for ≥2 weeks, 44.6% received >20 mg prednisone equivalents daily. Prophylaxis rates were low, with higher glucocorticoid doses associated with lower prophylaxis odds.

> **中文摘要：**
> 糖皮质激素、合并疾病以及免疫抑制治疗对耶氏肺孢子菌肺炎风险的影响仍缺乏充分研究，同时预防性治疗的使用不足。在 TriNetX 数据库中接受糖皮质激素治疗持续两周或以上的美国成年人中，44.6% 每日接受的泼尼松当量剂量超过 20 毫克。总体预防率较低，且更高剂量的糖皮质激素使用者其接受预防性治疗的可能性更低。

### 第二部分 AI 大师评价

本研究旨在评估糖皮质激素使用、伴随免疫抑制及合并症对耶氏肺孢子菌肺炎预防措施的影响。基于美国 TriNetX 数据库的大样本分析揭示，尽管相当比例患者接受高剂量糖皮质激素，但预防性治疗仍然明显不足。结果提示临床实践中存在预防策略的落实缺口，尤其是在高危人群中。研究的创新点在于提供了真实世界中大规模数据的风险与防治评估，但研究仍受限于回顾性设计及处方记录的不完全性。

---

## 11. 肺移植后高氨血症综合征的血清氨筛查与供体支原体检测：一项前瞻性观察研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39985813)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 39985813
**DOI：** 10.1093/cid/ciaf078

### 第一部分 原文与翻译

**英文原标题：** Serum Ammonia Screening and Donor Mollicutes Detection for Hyperammonemia Syndrome Post-Lung Transplantation: A Prospective Observational Study.

> **英文摘要：**
> BACKGROUND: Hyperammonemia syndrome (HS) is a rare but potentially fatal complication of lung transplantation (LT). Optimal screening methods are unknown. Here we investigated serum ammonia screening (SAS) for HS and compared it with polymerase chain reaction (PCR) for Mollicutes (Urease-producing bacteria).
> 
> METHODS: All LT recipients from July 2019 to February 2020 and October 2021 to November 2022 with available donor bronchial wash samples from the LT biobank were included. Mollicutes PCR was performed using 2 commercially available kits. Daily ammonia serum levels were measured for the first 14 days. Recipients were prospectively followed for HS for 30 days post-LT. HS was defined by new neurological symptoms and the presence of elevated serum ammonia (>1 × >70 µmol/L).
> 
> RESULTS: Of 241 LT recipients, 5 (2%) developed HS within the first month post-LT. Median time to HS was 8 (interquartile range, 5-10) days. All HS was diagnosed within the first 14 days post-LT, while daily SAS was in place. Ammonia was confirmed elevated (>1 × >70 µmol/L) in 4% (9/241) during follow-up; however, outside of HS, 4 were found to be related to liver disease. Donor and recipient Mollicutes PCR was positive in 8% (19/241) and 1% (1/72), respectively, at transplant. Donor Mollicutes PCR, in contrast to recipient Mollicutes PCR, was associated with HS but only in 2 of the 5 HS cases. No HS patient died within 90 days post-LT.
> 
> CONCLUSIONS: HS was a rare complication in our LT cohort. Daily post-LT SAS might add to early HS diagnosis and treatment and is potentially associated with improved outcome. Donor screening with Mollicutes PCR has limited predictive value for HS post-LT.

> **中文摘要：**
> 背景：高氨血症综合征（HS）是肺移植（LT）后罕见但潜在致命的并发症，最佳筛查方法尚不明确。本研究探讨了血清氨筛查（SAS）对HS的价值，并将其与检测尿素酶产生菌的支原体（Mollicutes）聚合酶链反应（PCR）进行比较。
> 
> 方法：纳入2019年7月至2020年2月及2021年10月至2022年11月期间所有具有供体支气管灌洗样本并存入移植生物样本库的肺移植受者。使用两种商业化检测试剂盒进行支原体PCR检测。在移植后前14天每日检测血清氨水平。受者在移植后30天内前瞻性随访HS的发生。HS定义为出现新的神经系统症状并伴有血清氨水平升高（>1×>70 μmol/L）。
> 
> 结果：在241例肺移植受者中，5例（2%）于术后首月内发生HS。HS中位发生时间为8天（四分位数间距5–10天）。所有HS病例均在术后14天内、每日SAS监测期间确诊。随访期间4%（9/241）的病例血氨升高（>1×>70 μmol/L）；但除HS外，其中4例与肝脏疾病相关。移植时供体和受体支原体PCR阳性率分别为8%（19/241）和1%（1/72）。供体支原体PCR阳性与HS相关，而受体阳性无相关性，但仅在5例HS中有2例检测到供体阳性。无HS患者在术后90天内死亡。
> 
> 结论：HS在本肺移植受者队列中为罕见并发症。术后每日血清氨筛查可能有助于HS的早期诊断与治疗，并潜在改善预后。供体支原体PCR筛查对术后HS的预测价值有限。

### 第二部分 AI 大师评价

该研究针对肺移植后罕见但严重的高氨血症综合征，前瞻性评估了血清氨每日筛查与供体支原体PCR检测的临床价值。结果表明，血清氨筛查有助于术后早期发现HS并促进及时干预，而供体支原体检测的预测作用有限。研究设计严谨，数据来自连续病例，具有较高的临床参考价值，但受样本量和时间窗口限制，仍需更大规模研究验证。

---

## 12. 免疫功能受损与未受损宿主中巴贝虫病结局的比较：一项多中心队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39873391)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 39873391
**DOI：** 10.1093/cid/ciaf034

### 第一部分 原文与翻译

**英文原标题：** Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study.

> **英文摘要：**
> BACKGROUND: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients.
> 
> METHODS: This multicenter retrospective cohort study included adult patients with laboratory-confirmed babesiosis from 2009 to 2023. Complications, management, and outcomes were compared between patients with IC/AH (ICAH) and without ICAH (immune intact cohort).
> 
> RESULTS: Of 225 patients (mean age 66 years, 36% female), 112 were ICAH. ICAH patients had higher median peak parasitemia (2.8% vs 0.9%, P < .0001) and higher rates of complications, including acute kidney injury (24% vs 11%, P = .016) and acute respiratory distress syndrome (11% vs 4%, P = .041), and were more likely to undergo packed red blood cell transfusion (31% vs 17%, P = .023) and exchange transfusion (18% vs 6%, P = .008). Treatment duration was longer in the ICAH cohort (median 27 vs 10 days, P < .001), particularly in those with both IC and AH (median 43 days, P = .003). ICAH patients had higher 12-month all-cause mortality (7% vs 1%, P = .019) and recurrence rates (8% vs 0%, P = .001). Hematologic malignancy (odds ratio = 7.0, P = .023) and B-cell-depleting therapies (odds ratio = 9.4, P = .015) were significant predictors of recurrence. Despite most patients undergoing follow-up testing with blood smears and polymerase chain reaction, these did not reliably predict recurrence.
> 
> CONCLUSIONS: Patients with ICAH with babesiosis experience more severe disease and higher complication rates. Follow-up testing, including blood smear and polymerase chain reaction, did not reliably predict recurrence, highlighting the need for more effective monitoring strategies in these high-risk populations.

> **中文摘要：**
> 背景：巴贝虫病对具有免疫功能受损状况（IC）及无脾/脾功能低下（AH）个体带来显著的不良结局风险。本研究比较了这些易感人群与免疫功能正常患者之间的临床结局差异。
> 
> 方法：这项多中心回顾性队列研究纳入了2009年至2023年间实验室确诊的成年巴贝虫病患者。研究比较了存在IC/AH（ICAH）和不存在ICAH（免疫完整队列）患者之间的并发症、治疗管理及临床结局。
> 
> 结果：在225例患者中（平均年龄66岁，女性占36%），112例为ICAH患者。ICAH患者的寄生虫血症峰值中位数更高（2.8% vs 0.9%，P < .0001），并且并发症发生率更高，包括急性肾损伤（24% vs 11%，P = .016）和急性呼吸窘迫综合征（11% vs 4%，P = .041），且更可能接受浓缩红细胞输注（31% vs 17%，P = .023）和换血治疗（18% vs 6%，P = .008）。ICAH队列的治疗持续时间更长（中位数27天 vs 10天，P < .001），尤其是同时存在IC和AH的患者（中位数43天，P = .003）。ICAH患者的12个月全因死亡率更高（7% vs 1%，P = .019），复发率亦更高（8% vs 0%，P = .001）。血液系统恶性肿瘤（比值比=7.0，P = .023）和B细胞消耗治疗（比值比=9.4，P = .015）是复发的重要预测因素。尽管大多数患者接受了血涂片和聚合酶链反应（PCR）随访检测，但这些检测未能可靠预测复发。
> 
> 结论：伴有ICAH的巴贝虫病患者病情更为严重，并发症发生率更高。包括血涂片和PCR在内的随访检测未能可靠预测复发，提示亟需在高危人群中建立更有效的监测策略。

### 第二部分 AI 大师评价

本研究通过多中心回顾性队列方法，系统比较了免疫受损或无脾/脾功能低下患者与免疫完整患者中巴贝虫病的临床结局。结果显示，免疫受损相关群体具有更高的寄生虫血症水平、更严重的并发症和更高的死亡及复发风险，且常需更长疗程与强化治疗。研究揭示了血液系统恶性肿瘤和B细胞消耗治疗为复发的重要风险因素，提示现有随访检测无法有效判断复发。该研究为制定高危人群的精准监测与管理策略提供了重要依据，但作为回顾性分析，其因果推断仍有限。

---

速递结束，祝您工作愉快！